

Supplementary Table 1: Patient Characteristics

Pt	Age	Site of disease	Treatment	Response/Max	Time to Progression
1	68	sc	BRAF _i	SD (-25%)	5 months
2	68	n	BRAF _i	PR (-54%)	8.5 months
3	42	sc	BRAF _i	SD	4.5 months
4	49	lu, sc	BRAF _i	PR (-56%)	3.5 months
5	74	n	BRAF _i	SD (-27%)	6.5 months
6	73	sc	BRAF _i + MEK _i	PR (-38%)	15 months, ongoing
7	56	sc, n	BRAF _i + MEK _i	CR	14 months, ongoing
8	37	sc, br	BRAF _i + MEK _i	PR (-30%)	5.5 months
9	36	n, br	BRAF _i + MEK _i	PR (-37%)	9 months
10	37	li, sc, n	BRAF _i + MEK _i	SD (-13%)	3 months
11	72	sc, br	BRAF _i + MEK _i	PR (-61%)	10 months
12	31	sc, br, n	BRAF _i + MEK _i	PR (-67%)	9 months, ongoing
13	69	sc, n	BRAF _i + MEK _i	PR (-42%)	9 months, ongoing
14	25	n, b	BRAF _i + MEK _i	PR (-61%)	15 months, lost to follow-up
16	41	n, sc, lu, li	BRAF _i + MEK _i	SD (-19.5%)	10 months
18	62	sc, n	BRAF _i + MEK _i	SD	6 months

sc = subcutaneous n = nodal lu = lung li = liver br = brain b = bone
 PR=partial response CR=complete response SD=stable disease